Adults age ≥ 18 years with AML, MDS, or MDS/MPN undergoing allo-HSCT at high risk for post-transplant relapse and MRD-positive. Patients with FLT3, IDH, or BCR-ABL-mutations excluded. This evidence concerns the gene ABL1 and acute myeloid leukemia.